Comparable stake leader
Inscobee Inc.
SEC ownership of Apimeds Pharmaceuticals US, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001894525.
Disclosed value leader
Inscobee Inc.
Comparable rows
2/9
Latest evidence
31 Dec 2025
- Public ticker
- APUS on NYSE
- Parsed ownership sources
-
3/4/5 and 13D/G
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Inscobee Inc.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
2 of 9
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Inscobee Inc.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
31 Dec 2025
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001894525
- Issuer location
- Matawan, NJ
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Apimeds Pharmaceuticals US, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Inscobee Inc.
Disclosed value leader
Inscobee Inc.
Comparable rows
2/9
Latest evidence
31 Dec 2025
3/4/5
13D/G
Lead comparable stake: 34%
7 rows are not safely comparable across share classes.
13D/G row: Inscobee Inc.
Showing 1-8 of 9 holder rows.
Quick read
Inscobee Inc. leads the comparable SEC ownership view at 34%.
2 of 9 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Inscobee Inc.'s linked filing trail.
Comparable ownership
Top 2
Inscobee Inc.
34%
Ayrton Capital LLC
10%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 9 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Inscobee Inc. |
3/4/5
13D/G
10%+ Owner · Apimeds Inc.
|
34%
from 13D/G
|
$8,805,900
4,316,618 shares
|
— | 12 May 2025 |
| Ayrton Capital LLC |
13D/G
|
10%
|
$2,612,429
1,397,021 shares
|
$0 | 31 Dec 2025 |
| Erik C. Emerson |
3/4/5
Chief Executive Officer, Director
|
—
mixed-class rows
|
$1,312,500
965,000 shares
mixed-class rows
|
— | 15 Oct 2025 |
| Christopher Kim |
3/4/5
Chairman and CMO, Director
|
—
mixed-class rows
|
$485,625
280,500 shares
mixed-class rows
|
— | 15 Oct 2025 |
| Jakap Koo |
3/4/5
Director
|
—
mixed-class rows
|
—
653,885 shares
mixed-class rows
|
— | 11 Nov 2025 |
| Bennett Weintraub |
3/4/5
Director
|
—
class O/S missing
|
—
10,000 shares
|
— | 11 Nov 2025 |
| Carol A. O'Donnell |
3/4/5
Director
|
—
class O/S missing
|
—
10,000 shares
|
— | 11 Nov 2025 |
| Elona Kogan |
3/4/5
Director
|
—
class O/S missing
|
—
10,000 shares
|
— | 11 Nov 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 16 Aug 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-9 of 9 reporting-owner rows connected to Apimeds Pharmaceuticals US, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
9
Largest Forms 3/4/5 holder
Inscobee Inc.
Net 12M change
$0
Latest report
11 Nov 2025
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Inscobee Inc. | 10%+ Owner | $8,805,900 | Mixed | 12 May 2025 | ||
| Erik C. Emerson | Chief Executive Officer, Director | $1,312,500 | Mixed | 15 Oct 2025 | ||
| Christopher Kim | Chairman and CMO, Director | $485,625 | Mixed | 15 Oct 2025 | ||
| Mark Corrao | Chief Financial Officer | Mixed | 04 Mar 2025 | |||
| Carol A. O'Donnell | Director | Mixed | 11 Nov 2025 | |||
| Jakap Koo | Director | Mixed | 11 Nov 2025 | |||
| Elona Kogan | Director | Mixed | 11 Nov 2025 | |||
| Hankil Yoon | Director | Mixed | 11 Nov 2025 | |||
| Bennett Weintraub | Director | Mixed | 11 Nov 2025 |
Recent insider transactions for Apimeds Pharmaceuticals US, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Jakap Koo | APUS | Stock Option (right to buy) | Award | 10,000 | 10,000 | 11 Nov 2025 | Direct | |||
| Hankil Yoon | APUS | Stock Option (right to buy) | Award | 10,000 | 10,000 | 11 Nov 2025 | Direct | |||
| Bennett Weintraub | APUS | Stock Option (right to buy) | Award | 10,000 | 10,000 | 11 Nov 2025 | Direct | |||
| Elona Kogan | APUS | Stock Option (right to buy) | Award | 10,000 | 10,000 | 11 Nov 2025 | Direct | |||
| Carol A. O'Donnell | APUS | Stock Option (right to buy) | Award | 10,000 | 10,000 | 11 Nov 2025 | Direct | |||
| Elona Kogan | APUS | Stock Option (right to buy) | Award | 3,000 | 3,000 | 15 Oct 2025 | Direct | |||
| Carol A. O'Donnell | APUS | Stock Option (right to buy) | Award | 3,000 | 3,000 | 15 Oct 2025 | Direct | |||
| Jakap Koo | APUS | Stock Option (right to buy) | Award | 3,000 | 3,000 | 15 Oct 2025 | Direct | |||
| Bennett Weintraub | APUS | Stock Option (right to buy) | Award | 3,000 | 3,000 | 15 Oct 2025 | Direct | |||
| Christopher Kim | APUS | Stock Option (right to buy) | Award | 3,000 | 3,000 | 15 Oct 2025 | Direct | |||
| Hankil Yoon | APUS | Stock Option (right to buy) | Award | 3,000 | 3,000 | 15 Oct 2025 | Direct | |||
| Erik C. Emerson | APUS | Stock Option (right to buy) | Award | 215,000 | 215,000 | 15 Oct 2025 | Direct |
* marks a reported price that did not pass the local price check.